IceCure's Cryoablation Study Shows Strong Long-Term Efficacy in Kidney Cancer Treatment
Event summary
- IceCure Medical reported 83.9% recurrence-free rate at median 4-year follow-up in ICESECRET study for kidney cancer cryoablation.
- Subgroup with tumors ≤3 cm showed 89.4% recurrence-free rate.
- Full study results to be presented at European Conference of Interventional Oncology 2026 in April.
- ProSense® system already approved in U.S., Europe, and other key markets for kidney tumor treatment.
The big picture
The study results reinforce the growing trend toward minimally invasive, nephron-sparing treatments for kidney cancer, particularly for elderly patients and those with comorbidities. With over 400,000 new kidney cancer cases globally and 80,000 in the U.S. alone, the unmet need for effective, non-surgical options is substantial. IceCure's technology could capture significant market share if these outcomes are replicated in broader clinical practice.
What we're watching
- Commercial Adoption
- Whether these positive results will accelerate ProSense® adoption in approved markets.
- Regulatory Expansion
- The pace at which IceCure can secure approvals for additional indications.
- Competitive Positioning
- How this data positions IceCure against surgical alternatives and other cryoablation technologies.
Related topics